Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma

Mikayel Mkrtichyan, Anahit Ghochikyan, Hayk Davtyan, Nina Movsesyan, Dmitry Loukinov, Victor Lobanenkov, David H. Cribbs, Amanda K. Laust, Edward L. Nelson, Michael G. Agadjanyan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Here, we analyze for the first time the immunological and therapeutic efficacy of a dendritic cell (DC) vaccine based on a cancer-testis antigen, Brother of regulator of imprinted sites (BORIS), an epigenetically acting tumor-promoting transcription factor. Vaccination of mice with DC loaded with truncated form of BORIS (DC/mBORIS) after 4T1 mammary tumor implantation induced strong anti-cancer immunity, inhibited tumor growth (18.75% of mice remained tumor-free), and dramatically lowered the number of spontaneous clonogenic metastases (50% of mice remained metastases-free). Higher numbers of immune effector CD4 and CD8 T cells infiltrated the tumors of vaccinated mice vs. control animals. Vaccination significantly decreased the number of myeloid-derived suppressor cells (MDSCs) infiltrating the tumor sites, but not MDSCs in the spleens of vaccinated animals. These data suggest that DC-based mBORIS vaccination strategies have significant anti-tumor activity in a therapeutic setting and will be more effective when combined with agents to attenuate tumor-associated immune suppression.

Original languageEnglish (US)
Pages (from-to)188-197
Number of pages10
JournalCellular Immunology
Volume270
Issue number2
DOIs
StatePublished - Jun 6 2011

Fingerprint

Testicular Neoplasms
Dendritic Cells
Vaccines
Breast Neoplasms
Antigens
Neoplasms
Vaccination
Breast Implantation
Neoplasm Metastasis
Immunity
Transcription Factors
Spleen
T-Lymphocytes
Therapeutics
Growth

Keywords

  • 4T1 mammary carcinoma
  • Brother of regulator of imprinted sites (BORIS)
  • Dendritic cell (DC)-based vaccine
  • Immunotherapy of breast cancer
  • Myeloid derived suppressor cells (MDSC)
  • Tumor promoting transcription factor

ASJC Scopus subject areas

  • Immunology

Cite this

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. / Mkrtichyan, Mikayel; Ghochikyan, Anahit; Davtyan, Hayk; Movsesyan, Nina; Loukinov, Dmitry; Lobanenkov, Victor; Cribbs, David H.; Laust, Amanda K.; Nelson, Edward L.; Agadjanyan, Michael G.

In: Cellular Immunology, Vol. 270, No. 2, 06.06.2011, p. 188-197.

Research output: Contribution to journalArticle

Mkrtichyan, M, Ghochikyan, A, Davtyan, H, Movsesyan, N, Loukinov, D, Lobanenkov, V, Cribbs, DH, Laust, AK, Nelson, EL & Agadjanyan, MG 2011, 'Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma', Cellular Immunology, vol. 270, no. 2, pp. 188-197. https://doi.org/10.1016/j.cellimm.2011.05.007
Mkrtichyan, Mikayel ; Ghochikyan, Anahit ; Davtyan, Hayk ; Movsesyan, Nina ; Loukinov, Dmitry ; Lobanenkov, Victor ; Cribbs, David H. ; Laust, Amanda K. ; Nelson, Edward L. ; Agadjanyan, Michael G. / Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. In: Cellular Immunology. 2011 ; Vol. 270, No. 2. pp. 188-197.
@article{8bef52d6d8e748c19e94535298b96949,
title = "Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma",
abstract = "Here, we analyze for the first time the immunological and therapeutic efficacy of a dendritic cell (DC) vaccine based on a cancer-testis antigen, Brother of regulator of imprinted sites (BORIS), an epigenetically acting tumor-promoting transcription factor. Vaccination of mice with DC loaded with truncated form of BORIS (DC/mBORIS) after 4T1 mammary tumor implantation induced strong anti-cancer immunity, inhibited tumor growth (18.75{\%} of mice remained tumor-free), and dramatically lowered the number of spontaneous clonogenic metastases (50{\%} of mice remained metastases-free). Higher numbers of immune effector CD4 and CD8 T cells infiltrated the tumors of vaccinated mice vs. control animals. Vaccination significantly decreased the number of myeloid-derived suppressor cells (MDSCs) infiltrating the tumor sites, but not MDSCs in the spleens of vaccinated animals. These data suggest that DC-based mBORIS vaccination strategies have significant anti-tumor activity in a therapeutic setting and will be more effective when combined with agents to attenuate tumor-associated immune suppression.",
keywords = "4T1 mammary carcinoma, Brother of regulator of imprinted sites (BORIS), Dendritic cell (DC)-based vaccine, Immunotherapy of breast cancer, Myeloid derived suppressor cells (MDSC), Tumor promoting transcription factor",
author = "Mikayel Mkrtichyan and Anahit Ghochikyan and Hayk Davtyan and Nina Movsesyan and Dmitry Loukinov and Victor Lobanenkov and Cribbs, {David H.} and Laust, {Amanda K.} and Nelson, {Edward L.} and Agadjanyan, {Michael G.}",
year = "2011",
month = "6",
day = "6",
doi = "10.1016/j.cellimm.2011.05.007",
language = "English (US)",
volume = "270",
pages = "188--197",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma

AU - Mkrtichyan, Mikayel

AU - Ghochikyan, Anahit

AU - Davtyan, Hayk

AU - Movsesyan, Nina

AU - Loukinov, Dmitry

AU - Lobanenkov, Victor

AU - Cribbs, David H.

AU - Laust, Amanda K.

AU - Nelson, Edward L.

AU - Agadjanyan, Michael G.

PY - 2011/6/6

Y1 - 2011/6/6

N2 - Here, we analyze for the first time the immunological and therapeutic efficacy of a dendritic cell (DC) vaccine based on a cancer-testis antigen, Brother of regulator of imprinted sites (BORIS), an epigenetically acting tumor-promoting transcription factor. Vaccination of mice with DC loaded with truncated form of BORIS (DC/mBORIS) after 4T1 mammary tumor implantation induced strong anti-cancer immunity, inhibited tumor growth (18.75% of mice remained tumor-free), and dramatically lowered the number of spontaneous clonogenic metastases (50% of mice remained metastases-free). Higher numbers of immune effector CD4 and CD8 T cells infiltrated the tumors of vaccinated mice vs. control animals. Vaccination significantly decreased the number of myeloid-derived suppressor cells (MDSCs) infiltrating the tumor sites, but not MDSCs in the spleens of vaccinated animals. These data suggest that DC-based mBORIS vaccination strategies have significant anti-tumor activity in a therapeutic setting and will be more effective when combined with agents to attenuate tumor-associated immune suppression.

AB - Here, we analyze for the first time the immunological and therapeutic efficacy of a dendritic cell (DC) vaccine based on a cancer-testis antigen, Brother of regulator of imprinted sites (BORIS), an epigenetically acting tumor-promoting transcription factor. Vaccination of mice with DC loaded with truncated form of BORIS (DC/mBORIS) after 4T1 mammary tumor implantation induced strong anti-cancer immunity, inhibited tumor growth (18.75% of mice remained tumor-free), and dramatically lowered the number of spontaneous clonogenic metastases (50% of mice remained metastases-free). Higher numbers of immune effector CD4 and CD8 T cells infiltrated the tumors of vaccinated mice vs. control animals. Vaccination significantly decreased the number of myeloid-derived suppressor cells (MDSCs) infiltrating the tumor sites, but not MDSCs in the spleens of vaccinated animals. These data suggest that DC-based mBORIS vaccination strategies have significant anti-tumor activity in a therapeutic setting and will be more effective when combined with agents to attenuate tumor-associated immune suppression.

KW - 4T1 mammary carcinoma

KW - Brother of regulator of imprinted sites (BORIS)

KW - Dendritic cell (DC)-based vaccine

KW - Immunotherapy of breast cancer

KW - Myeloid derived suppressor cells (MDSC)

KW - Tumor promoting transcription factor

UR - http://www.scopus.com/inward/record.url?scp=80051667961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051667961&partnerID=8YFLogxK

U2 - 10.1016/j.cellimm.2011.05.007

DO - 10.1016/j.cellimm.2011.05.007

M3 - Article

C2 - 21641588

AN - SCOPUS:80051667961

VL - 270

SP - 188

EP - 197

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

IS - 2

ER -